Search in the Abstract Database

Search Abstracts 2011

* = Presenting author

P089. Large burden of disease in early CD-patients in the Biocrohn Registry in Germany

B. Bokemeyer1, U. Helwig2, A. Stallmach3, M. Düffelmeyer4, H. Raspe5, A. Prenzler6, T. Mittendorf6, D. Hueppe7, S. Nikolaus8, S. Schreiber8

1Gastroenterology Practice Minden/Department of General Medicine, Medical University of Schleswig-Holstein, Campus Kiel, Minden, Germany; 2Gastroenterology Practice, Oldenburg, Germany; 3University Hospital Jena, Department of Gastroenterology, Jena, Germany; 4IOMTech GmbH, Berlin, Germany; 5Institute of Social Medicine, Medical University of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany; 6Center for Health Economics, Leibnitz University Hannover, Hannover, Germany; 7Gastroenterology Practice Herne, Herne, Germany; 8Department of General Medicine, Medical University of Schleswig-Holstein, Campus Kiel, Kiel, Germany

Aim: The Biocrohn Registry (Biological Registry with Crohn's Disease Patients in Germany) of the Competence-Network CED is a three-year prospective registration of severe side-effects under newly introduced therapy with biologicals for patients suffering from Crohn's disease (CD) in Germany. Concomitantly, an early-disease group of CD patients is being prospectively documented. At the middle of 2010, about 450 patients had been included in the Biocrohn study. Further recruiting will be continued until the end of 2011. In the intermediate analysis of a sub-group of the Biocrohn study, the clinical data of 198 CD-patients with early disease will be presented.

Materials and Methods: Within the framework of this non-interventional prospective online documentation, data on the course of the disease, on psychosocial disease burdens, on health economy and on the genetic profile will be examined. The investigator network includes consecutively CD patients after new introduction of biologicals or early disease patients (first diagnosis <3 years), respectively. Presently the registry aims at 1000 patients with 3 years of follow up. Extensions are possible.

Results: 455 patients were available for this intermediate analysis: 198 in the early-disease group and 257 in the biologicals group. The average age of the early-disease group was 30 years (biologicals: 36 years), and the duration of the disease was two years (biologics: 9 years). The following therapies were registered during the admission in the early-disease group: 41.4% 5-ASA, 24.2% budesonide, 15.2% systemic glucocorticoid therapy, 39.4% immunosuppressive drugs and 14.1% anti-TNF. Only 53.0% of the patients were clinically in remission. 63.1% pursued an active employment and 25.3% of the patients suffered from sub-depression/depression. According to the Vienna classification, inflammation driven disease was found in 77.5% of patients.

Conclusion: Only approximately half of the early disease cases were in clinical remission, although immunosuppressive (39.4%) or anti-TNF (14.1%) drugs were administered in most patients. Although intended only as a control group for side effects the early disease group shows an unexpectedly high (co)morbidity, indicating a reduced health state already in early Crohn's disease.